Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04817826
Title TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC. (INFINITY)
Acronym INFINITY
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Gruppo Oncologico del Nord-Ovest
Indications
Therapies
Age Groups: adult | senior
Covered Countries ITA

Additional content available in CKB BOOST